Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 14, 2009
Event: Entry into a Material Definitive Agreement for a private placement of common stock.
Key Financial Metrics and Transaction Details
This filing reports a specific capital raise transaction rather than periodic financial performance metrics (revenue, profit, cash flow, or margins are not disclosed in this document).
- Investor: Seaside 88, LP
- Shares Issued: 2,352,941 shares of common stock
- Price Per Share: $0.85
- Aggregate Value: $2,000,000
- Discount: 5.5% below the closing price on December 14, 2009
- Transaction Costs: $25,000 payable to Seaside 88, LP for legal expenses
Material Changes and Conditions
The transaction is contingent upon the following conditions:
- SEC Registration: The sale is contingent on the effectiveness of a registration statement on Form S-1 (File No. 333-162781) filed on October 30, 2009.
- Closing Timeline: Expected to close within two days of the registration statement being declared effective.
- Deadline: The stock sale must close by December 31, 2009.
- Indemnification: Nephros, Inc. agreed to indemnify Seaside 88, LP against certain liabilities related to the sale.
Outlook, Risks, and Management Commentary
Management Commentary: The filing serves as a summary of the agreement terms and references the full text of the Common Stock Purchase Agreement (Exhibit 10.52) for complete details.
Risks and Contingencies: The primary risk is the failure of the SEC to declare the registration statement effective by the December 31, 2009 deadline, which would prevent the closing of the transaction. The filing does not provide specific guidance on future revenue or operational outlook beyond this capital raise.
Investor Verification Checklist
- Verify the status of Form S-1 (File No. 333-162781) to confirm if it has been declared effective by the SEC.
- Confirm whether the transaction closed by the December 31, 2009 deadline.
- Review the full text of the Common Stock Purchase Agreement (Exhibit 10.52) for specific indemnification liabilities and customary closing conditions.
- Check subsequent filings to confirm the issuance of the 2,352,941 shares and the receipt of $2,000,000 in proceeds.